TherapeuticsMD gears up to launch first-ever bioidentical hormone combo Bijuva

Stamp with blue ink that says "FDA Approved"
The FDA has approved TherapeuticsMD's Bijuva, the first bioidentical combo of estradiol and progesterone. (Olivier Le Moal/Getty Images)

TherapeuticsMD just racked up its third FDA approval of the year, this time for a menopause remedy that combines two bioidentical hormones.

The agency cleared Bijuva, an oral softgel that contains estradiol and progesterone, two commonly used hormone therapies, to alleviate menopause symptoms such as hot flashes. TherapeuticsMD's ingredients are artificially produced but chemically identical to hormones made naturally by women's bodies.

As the women’s health-focused company’s third FDA nod this year—following Imvexxy, a bioidentical estradiol vaginal insert, and Annovera, a hormonal birth control ring—Bijuva will roll out in the second quarter of 2019. The company said the target date allows it to build up the foundation for its launch.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

“We will expand our salesforce in Q1 to cover the more significant market opportunity for Bijuva, as well as activate payer discussions to ensure coverage ramp is in line with our expectations,” a spokesperson told FiercePharma via email.

The company hasn't yet set a price, but it expects “to price at parity to the other drugs in the market despite the other compounds being older drugs,” the spokesperson said.

Bijuva is the first bioidentical combo hormone therapy the FDA has approved, the company said. The agency has greenlighted separate estradiol and progesterone pills that are bioidentical, but not intended to be used together. Synthetic versions of that combo are available, however, and some compounded bioidentical hormones are circulating on the market, TherapeuticsMD said.

Although there’s currently no evidence showing bioidentical therapies are better than synthetic hormones, the Florida company thinks there’s still a meaningful market up for grabs.

Citing data from IQVIA and a consensus estimate from Symphony Health Solutions, TherapeuticsMD figures that the separate bioidentical drugs, plus the compounded versions, together account for 15 million to 20 million dispensed prescriptions each year in the U.S. These are the easier targets because Bijuva can save patients out-of-pocket costs via insurance coverage and can eliminate risks of compounded hormone therapy, the company argues.

“Bijuva addresses a significant demand for bioidentical hormone therapy and provides women, their healthcare providers and pharmacists with a proven bi-identical combination product that can be covered by their insurance,” said company CEO Robert Finizio in a statement.

As the first phase of its launch plan, the company started an outreach program called Bio-Ignite. The aim is to reach some 3,000 high-volume compounding pharmacies to garner their interest in replacing their compounded bioidentical estradiol and progesterone with Bijuva.

Suggested Articles

Alcon has many "mass and structural advantages" over "distant" follower Bausch, which spends a lot less on R&D, says one analyst.

The judge in a multistate case against opioid makers scoffed at their request for more time to review an estimate that they owe $480 billion in damages.

Indian drugmakers pick up U.S. generics scripts; Chi-Med files for Hong Kong listing; an explosion at a Qilu Pharma subsidiary kills 10.